Sisson J H, Yonkers A J, Waldman R H
Department of Medicine, University of Nebraska Medical Center, Omaha 68198-5300.
Chest. 1995 Mar;107(3):747-51. doi: 10.1378/chest.107.3.747.
Mucociliary clearance is an important host defense function of the upper respiratory tract that requires the coordinated beating of cilia and results in the transport of mucus to the oropharynx. Guaifenesin is a commonly prescribed drug that is reported to improve the clearance of respiratory secretions. We hypothesized that guaifenesin increases nasal mucociliary clearance related to increases in ciliary beat frequency (CBF) and that a direct relationship exists between nasal CBF and nasal mucociliary clearance.
Double-blind placebo-controlled crossover study.
Ten healthy volunteers with a previous history of sinus disease.
Subjects received guaifenesin or placebo on days 1 to 7 or days 14 to 21.
In vivo saccharine transit time (STT) was measured by noting the time in minutes required for the subject to taste a saccharin particle placed on the inferior turbinate of the naris. The CBF was determined by video microscopy on ten separate groups of beating ciliated nasal mucosal cells obtained by brushing immediately after each STT determination. We found that there was no significant change between the guaifenesin-or placebo-treated groups from baseline values of STT (p = 0.94) or CBF (p = 0.46). Regression analysis demonstrated no relationship between STT and CBF for repeated measures within subjects (mean r2 = 0.18; mean p = 0.66) and between STT and CBF when all paired measurements were combined across subjects (r2 = 0.47; p = 0.46).
We conclude that guaifenesin exerts no measurable effect on in vivo nasal mucociliary clearance or ex vivo nasal ciliary motility in healthy volunteers with previous sinus disease. In addition, there appears to be no relationship between nasal STT measured in vivo and CBF measured ex vivo. The lack of correlation is most likely due to variations in CBF related to sampling artifacts introduced by the nasal brushing process.
黏液纤毛清除功能是上呼吸道一项重要的宿主防御功能,该功能需要纤毛协调摆动,促使黏液运送至口咽。愈创甘油醚是一种常用药物,据报道可改善呼吸道分泌物的清除。我们推测,愈创甘油醚可通过增加纤毛摆动频率(CBF)来提高鼻腔黏液纤毛清除功能,且鼻腔CBF与鼻腔黏液纤毛清除功能之间存在直接关系。
双盲安慰剂对照交叉研究。
10名有鼻窦疾病既往史的健康志愿者。
受试者在第1至7天或第14至21天接受愈创甘油醚或安慰剂治疗。
通过记录受试者品尝置于鼻腔下鼻甲的糖精颗粒所需的分钟数来测量体内糖精转运时间(STT)。在每次STT测定后立即通过刷取获取十组单独的摆动纤毛的鼻黏膜细胞,利用视频显微镜确定CBF。我们发现,愈创甘油醚治疗组和安慰剂治疗组的STT基线值(p = 0.94)或CBF(p = 0.46)之间无显著变化。回归分析表明,受试者内重复测量的STT与CBF之间无相关性(平均r2 = 0.18;平均p = 0.66),所有受试者的配对测量结果合并后,STT与CBF之间也无相关性(r2 = 0.47;p = 0.46)。
我们得出结论,愈创甘油醚对有鼻窦疾病既往史的健康志愿者的体内鼻腔黏液纤毛清除功能或体外鼻腔纤毛运动无显著影响。此外,体内测量的鼻腔STT与体外测量的CBF之间似乎无相关性。缺乏相关性很可能是由于鼻腔刷取过程引入的采样假象导致CBF存在差异。